Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Sell
19
XFOR Quote, Financials, Valuation and Earnings
Last price:
$3.71
Seasonality move
:
-5.35%
Day range:
$3.58 - $3.72
52-week range:
$1.35 - $24.43
Dividend yield:
0%
P/E ratio:
0.70x
P/S ratio:
1.72x
P/B ratio:
5.15x
Volume:
240.2K
Avg. volume:
629.6K
1-year change:
-74.66%
Market cap:
$317.4M
Revenue:
$2.6M
EPS (TTM):
-$10.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XFOR
X4 Pharmaceuticals, Inc.
|
$1.7M | -$0.34 | 20.85% | -94.18% | $8.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.37 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XFOR
X4 Pharmaceuticals, Inc.
|
$3.63 | $8.00 | $317.4M | 0.70x | $0.00 | 0% | 1.72x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3.15 | $0.85 | $397.4M | 5.29x | $0.80 | 0% | 6.12x |
|
NNVC
NanoViricides, Inc.
|
$1.11 | $6.50 | $20M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.81 | $2.00 | $662.7K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.20 | $7.00 | $6.8M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XFOR
X4 Pharmaceuticals, Inc.
|
55.66% | 2.478 | 89.95% | 5.25x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.780 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | 0.905 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -2.522 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XFOR
X4 Pharmaceuticals, Inc.
|
$1.4M | -$27.5M | -84.9% | -279.19% | -1558.58% | -$27.8M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
X4 Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns XFOR or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of -255.85%. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital XFORX4 Pharmaceuticals, Inc.78.81% -$0.69 $139M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About XFOR or NBY?
X4 Pharmaceuticals, Inc. has a consensus price target of $8.00, signalling upside risk potential of 120.39%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -73.02%. Given that X4 Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe X4 Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XFORX4 Pharmaceuticals, Inc.3 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is XFOR or NBY More Risky?
X4 Pharmaceuticals, Inc. has a beta of 0.412, which suggesting that the stock is 58.772% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock XFOR or NBY?
X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XFOR or NBY?
X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 5.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 1.72x versus 6.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XFORX4 Pharmaceuticals, Inc.1.72x 0.70x $1.8M -$29.8M NBYNovaBay Pharmaceuticals, Inc.6.12x 5.29x $521K -$1.3M
-
Which has Higher Returns XFOR or NNVC?
NanoViricides, Inc. has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of --. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital XFORX4 Pharmaceuticals, Inc.78.81% -$0.69 $139M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About XFOR or NNVC?
X4 Pharmaceuticals, Inc. has a consensus price target of $8.00, signalling upside risk potential of 120.39%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 485.59%. Given that NanoViricides, Inc. has higher upside potential than X4 Pharmaceuticals, Inc., analysts believe NanoViricides, Inc. is more attractive than X4 Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XFORX4 Pharmaceuticals, Inc.3 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is XFOR or NNVC More Risky?
X4 Pharmaceuticals, Inc. has a beta of 0.412, which suggesting that the stock is 58.772% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.439%.
-
Which is a Better Dividend Stock XFOR or NNVC?
X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XFOR or NNVC?
X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are larger than NanoViricides, Inc. quarterly revenues of --. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 1.72x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XFORX4 Pharmaceuticals, Inc.1.72x 0.70x $1.8M -$29.8M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns XFOR or OGEN?
Oragenics, Inc. has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of --. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital XFORX4 Pharmaceuticals, Inc.78.81% -$0.69 $139M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About XFOR or OGEN?
X4 Pharmaceuticals, Inc. has a consensus price target of $8.00, signalling upside risk potential of 120.39%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 148.36%. Given that Oragenics, Inc. has higher upside potential than X4 Pharmaceuticals, Inc., analysts believe Oragenics, Inc. is more attractive than X4 Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XFORX4 Pharmaceuticals, Inc.3 0 0 OGENOragenics, Inc.1 0 0 -
Is XFOR or OGEN More Risky?
X4 Pharmaceuticals, Inc. has a beta of 0.412, which suggesting that the stock is 58.772% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.685%.
-
Which is a Better Dividend Stock XFOR or OGEN?
X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XFOR or OGEN?
X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are larger than Oragenics, Inc. quarterly revenues of --. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 1.72x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XFORX4 Pharmaceuticals, Inc.1.72x 0.70x $1.8M -$29.8M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns XFOR or PTN?
Palatin Technologies has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of --. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XFORX4 Pharmaceuticals, Inc.78.81% -$0.69 $139M PTNPalatin Technologies-- -- -- -
What do Analysts Say About XFOR or PTN?
X4 Pharmaceuticals, Inc. has a consensus price target of $8.00, signalling upside risk potential of 120.39%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than X4 Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than X4 Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XFORX4 Pharmaceuticals, Inc.3 0 0 PTNPalatin Technologies0 0 0 -
Is XFOR or PTN More Risky?
X4 Pharmaceuticals, Inc. has a beta of 0.412, which suggesting that the stock is 58.772% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock XFOR or PTN?
X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XFOR or PTN?
X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are larger than Palatin Technologies quarterly revenues of --. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is higher than Palatin Technologies's net income of --. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 1.72x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XFORX4 Pharmaceuticals, Inc.1.72x 0.70x $1.8M -$29.8M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns XFOR or TOVX?
Theriva Biologics, Inc. has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of --. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital XFORX4 Pharmaceuticals, Inc.78.81% -$0.69 $139M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About XFOR or TOVX?
X4 Pharmaceuticals, Inc. has a consensus price target of $8.00, signalling upside risk potential of 120.39%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3386.06%. Given that Theriva Biologics, Inc. has higher upside potential than X4 Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than X4 Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XFORX4 Pharmaceuticals, Inc.3 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is XFOR or TOVX More Risky?
X4 Pharmaceuticals, Inc. has a beta of 0.412, which suggesting that the stock is 58.772% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.
-
Which is a Better Dividend Stock XFOR or TOVX?
X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XFOR or TOVX?
X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 1.72x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XFORX4 Pharmaceuticals, Inc.1.72x 0.70x $1.8M -$29.8M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Is Palantir Stock Going to Crash?
AI and data analytics major Palantir (NASDAQ:PLTR) has become something…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Sell
50
CVLT alert for Jan 28
Commvault Systems, Inc. [CVLT] is down 31.22% over the past day.
Buy
73
BNAI alert for Jan 28
Brand Engagement Network, Inc. [BNAI] is down 16.85% over the past day.
Buy
71
SANM alert for Jan 27
Sanmina Corp. [SANM] is down 21.58% over the past day.
